Virometix has revealed encouraging Phase 1 data for their lead vaccine asset, V-212, a synthetic vaccine designed to prevent pneumococcal disease caused by Streptococcus pneumoniae. In parallel, ...

Kolkata: A cough and cold outbreak has left thousands of Kolkatans with a sore throat, choked voice and fever, caused by a ...

The Ibiza Ocean Club founder, 63, has recalled his near-fatal health scare which saw his spend seven weeks in hospital after ...

Eurofins Viracor announces the launch of a multiplexed bead-based assay to detect IgG responses to currently available pneumococcal vaccines, including the recently approved Pneumococcal 21-valent ...

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its ...

Dr Ray O’Connor takes a look at recent clinical articles on the importance of promoting vaccines for Measles, HIV, Gonorrhoea ...

Bacterial coinfections in adults hospitalized with RSV do not appear to exacerbate clinical outcomes or increase mortality rates.

V-212 was well tolerated. Adverse events were predominantly mild to moderate in intensity, with a trend for increasing incidence of systemic reactogenicity with increasing dose level. The incidence of ...

KI researcher Federico Iovino has been awarded the Pioneer Innovator Grant from the Novo Nordisk Foundation. Designed to fast ...

What starts as a minor inconvenience can snowball into chronic sinusitis, recurrent infections, and even more serious ENT ...

Select gut bacteria protect mice against post-influenza virus secondary bacterial pneumonia, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State ...